Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Chief Admin. Ofcr. & GC | March 04, 2026 | March 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,748 |
Ending reported balance
After 2026-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-04 · Exercise / conversion · Acquired 675 · Balance 10,025 Row 2 · 2026-03-04 · Tax withholding · Disposed 277 · Balance 9,748 F1: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-04 · Exercise / conversion · Disposed 675 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 6, 2026 21:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000003 · form4-03062026_090355.xml · derivative · entry 3 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 675 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 277 | $21.31 | $5,902.87 |
DisclosureSEC source: 0002063633-26-000003 · form4-03062026_090355.xml · nonDerivative · entry 2 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,748 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000003 · form4-03062026_090355.xml · nonDerivative · entry 1 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 33,600 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · derivative · entry 10 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,600 Underlying: Common Stock · 33,600 shares Expires 2036-03-02 F7 · derivative.exercise_date: 1/48 of the total option award shall vest monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on April 1, 2026. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · derivative · entry 9 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 Underlying: Common Stock · 4,200 shares Expires 2030-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total award annually, with the first tranche vesting on March 1, 2027, subject to continued service through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 2,356 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · derivative · entry 8 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,069 Underlying: Common Stock · 2,356 shares Expires 2029-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 2, 2026, subject to continued service through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 970 | $20.55 | $19,933.50 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 5 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,350 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs; does not represent a sale by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,356 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 4 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 842 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · derivative · entry 7 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,686 Underlying: Common Stock · 842 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · derivative · entry 6 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 551 | $20.47 | $11,278.97 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 3 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,964 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 842 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 2 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0002063633-26-000002 · form4-03032026_110346.xml · nonDerivative · entry 1 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 21:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 7,200 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0002063633-25-000006 · form4-12292025_091213.xml · derivative · entry 1 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,200 Underlying: Common Stock · 7,200 shares Expires 2035-12-23 F1 · derivative.exercise_date: 1/48 of the total option award shall vest monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 12:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 12,504 | $0.80 | $9,993.20 |
DisclosureSEC source: 0002063633-25-000004 · form4-10162025_121018.xml · nonDerivative · entry 1 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,737 F1 · balance_after: The reported total includes 2,500 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:05 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 94,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010381 · form4-04082025_080422.xml · derivative · entry 2 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,250 Underlying: Common Stock · 94,250 shares Expires 2029-03-02 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 2, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:05 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy) · Derivative | 101,500 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-25-010381 · form4-04082025_080422.xml · derivative · entry 1 Pauling David · CIK 0002063633 · Chief Admin. Ofcr. & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,500 Underlying: Common Stock · 101,500 shares Expires 2035-04-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on May 4, 2025, with 100% of the award being vested and exercisable on April 4, 2029, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.